MXPA02008654A - Formulaciones de ranolazina de liberacion prolongada. - Google Patents

Formulaciones de ranolazina de liberacion prolongada.

Info

Publication number
MXPA02008654A
MXPA02008654A MXPA02008654A MXPA02008654A MXPA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A
Authority
MX
Mexico
Prior art keywords
ranolazine
sustained release
release ranolazine
aqueous media
ranolazine formulations
Prior art date
Application number
MXPA02008654A
Other languages
English (en)
Spanish (es)
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24074628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02008654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MXPA02008654A publication Critical patent/MXPA02008654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA02008654A 2000-03-08 2001-03-07 Formulaciones de ranolazina de liberacion prolongada. MXPA02008654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine
PCT/US2001/007287 WO2001066093A2 (en) 2000-03-08 2001-03-07 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
MXPA02008654A true MXPA02008654A (es) 2004-09-06

Family

ID=24074628

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008654A MXPA02008654A (es) 2000-03-08 2001-03-07 Formulaciones de ranolazina de liberacion prolongada.

Country Status (16)

Country Link
US (1) US6479496B1 (enExample)
EP (1) EP1263439A2 (enExample)
JP (2) JP4108980B2 (enExample)
CN (1) CN1323664C (enExample)
AU (3) AU2001240092B8 (enExample)
BR (1) BR0109091A (enExample)
CA (1) CA2402222C (enExample)
CZ (1) CZ20022996A3 (enExample)
HU (1) HUP0204409A3 (enExample)
IL (1) IL151575A0 (enExample)
MX (1) MXPA02008654A (enExample)
NO (1) NO20024270L (enExample)
NZ (1) NZ521292A (enExample)
PL (1) PL357273A1 (enExample)
RU (1) RU2002126615A (enExample)
WO (1) WO2001066093A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) * 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ES2177601T3 (es) * 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Also Published As

Publication number Publication date
CA2402222A1 (en) 2001-09-13
HK1058003A1 (en) 2004-04-30
NO20024270L (no) 2002-11-06
BR0109091A (pt) 2005-02-15
IL151575A0 (en) 2003-04-10
AU4009201A (en) 2001-09-17
PL357273A1 (en) 2004-07-26
RU2002126615A (ru) 2004-03-20
WO2001066093A2 (en) 2001-09-13
JP2008069159A (ja) 2008-03-27
EP1263439A2 (en) 2002-12-11
JP2003525896A (ja) 2003-09-02
US6479496B1 (en) 2002-11-12
CN1443069A (zh) 2003-09-17
HUP0204409A3 (en) 2005-04-28
NZ521292A (en) 2008-07-31
CZ20022996A3 (cs) 2003-09-17
CN1323664C (zh) 2007-07-04
HUP0204409A2 (en) 2003-05-28
AU2001240092B2 (en) 2004-10-14
JP4108980B2 (ja) 2008-06-25
AU2008212005A1 (en) 2008-09-25
NO20024270D0 (no) 2002-09-06
CA2402222C (en) 2009-11-03
AU2001240092B8 (en) 2004-12-02
WO2001066093A3 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
WO2001066093A3 (en) Sustained release ranolazine formulations
WO2000013687A3 (en) Sustained release ranolazine formulations
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
AU2001263228A1 (en) Rapidly disintegrating solid oral dosage form
MY118371A (en) Tetrahydrolipstatin containing compositions
AU2989695A (en) Pharmaceutically stable oxaliplatinum preparation
YU86003A (sh) Jednodnevne formulacije oksikodona
NZ336436A (en) Solid dosage forms and method for ameliorating male erectile dysfunction
MX9709094A (es) Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.
IL143375A0 (en) Sustained release matrix systems for highly soluble drugs
GB0214845D0 (en) Pharmaceutical formulations containing zolmitriptan
AP2003002763A0 (en) Controlled release formulations for oral administration
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
IL132201A0 (en) Stabilized human papillomavirus formulations
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
IL157539A0 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AU4929400A (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
AU2001240001A1 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
AU4874301A (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms
MY152490A (en) New oral formulation

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights